MedPath

Comparing the two drug combinations namely propofol-ketamine with propofol-fentanyl for sedating the child during the procedure of inserting endoscope in the food pipe and small intestine

Not Applicable
Completed
Conditions
Health Condition 1: null- Patients requiring esophagogastroduodenoscopy
Registration Number
CTRI/2013/03/003472
Lead Sponsor
JIPMER
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
74
Inclusion Criteria

(1) Children 3 -12 years of age.

(2) Patients requiring diagnostic/therapeutic EGD.

Exclusion Criteria

The children with the following features will be excluded from the study:

(1) Allergy to the study drugs during earlier endoscopies/soya and egg allergy.

(2) Documented difficulty to achieve sedation despite maximum admissible doses of these drugs during earlier sedation.

(3) Hypertension /glaucoma.

(4) Neuropsychiatric disorders/encephalopathy that impair assessment during recovery.

(5) Difficult airway.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome: <br/ ><br> To compare the proportion of people who require additional doses of propofol in the first minute after sedation induction between the propofol - ketamine group and propofol - fentanyl group.Timepoint: Outcome assessed at the end of the study period.
Secondary Outcome Measures
NameTimeMethod
1. To compare the total additional doses of propofol needed in the first minute after sedation induction <br/ ><br>,the total dose of propofol needed to achieve optimal sedation for performing esophagogastroduodenoscopy <br/ ><br>,the frequency of the adverse effects occurring during period of sedation and recovery ,the need for reinsertion of the endoscope due to suboptimal sedation and the endoscopistâ??s satisfaction for the procedure when the two drug combinations are used. <br/ ><br>Timepoint: Outcome assessed at the end of the study period.
© Copyright 2025. All Rights Reserved by MedPath